Merck & Co., Inc. (MRK)
NYSE: MRK · IEX Real-Time Price · USD
131.19
+0.31 (0.24%)
At close: May 17, 2024, 4:00 PM
131.29
+0.10 (0.08%)
Pre-market: May 20, 2024, 9:04 AM EDT
Merck & Co. Employees
Merck & Co. had 72,000 employees on December 31, 2023. The number of employees increased by 3,000 or 4.35% compared to the previous year.
Employees
72,000
Change (1Y)
3,000
Growth (1Y)
4.35%
Revenue / Employee
$852,806
Profits / Employee
$32,028
Market Cap
332.28B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
Dec 31, 2018 | 69,000 | 0 | - |
Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
Dec 31, 2016 | 68,000 | 0 | - |
Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
MRK News
- 3 days ago - Cramer says these 10 stocks helped the Dow briefly crack 40,000 - CNBC
- 5 days ago - Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline - Business Wire
- 7 days ago - Merck stops skin cancer combination therapy testing in late-stage study - Reuters
- 7 days ago - Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma - Business Wire
- 11 days ago - Merck treatment for a type of uterus cancer fails trial - Reuters
- 11 days ago - Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent - Business Wire
- 12 days ago - Merck to Participate in the Bank of America Securities 2024 Healthcare Conference - Business Wire
- 14 days ago - Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region - GlobeNewsWire